NEW YORK (Reuters)—A new class of blood thinners that competes with widely used warfarin should get a boost next year when an “antidote” that can reverse the medications’ effects in an emergency is expected to enter the market, according to top U.S. heart doctors and investors. Xarelto, from Bayer AG and Johnson & Johnson, and…
Articles by Natasha Yetman
More Evidence Biomarkers Predict RA Relapse with DMARD Taper
NEW YORK (Reuters Health)—For rheumatoid arthritis (RA) patients in stable remission, a panel of inflammatory markers in blood can help predict the odds of relapse when disease-modifying anti-rheumatic drug (DMARD) therapy is tapered, say researchers from Germany. The multibiomarker disease activity (MBDA) score, when combined with anticitrullinated protein antibody (ACPA) testing, can predict relapse in…
People with Schizophrenia at Higher Risk of Osteoporosis
NEW YORK (Reuters Health)—Pooled data indicate that bone mineral density (BMD) is significantly lower in patients with schizophrenia than in healthy controls, according to Taiwanese researchers. Dr. Ping-Tao Tseng tells Reuters Health by email that the “evidence indicates the importance of further screening for the risk of osteoporosis in young-aged schizophrenic patients . . ….
Methotrexate for Ulcerative Colitis Yields Mixed Results
NEW YORK (Reuters Health)—Parenteral methotrexate was no better than placebo for achieving steroid-free remission of ulcerative colitis (UC) in the METEOR trial. But the drug should not be abandoned in all UC patients, researchers say. “Although METEOR failed to reach its primary endpoint, an important secondary endpoint was met. Our study suggests that methotrexate should…
NIH-Funded Trials Dip While Industry Trials Are on the Rise
(Reuters Health)—Every year since 2006 in the U.S., the number of clinical trials funded by the National Institutes of Health (NIH) has gone down, while the number of industry-funded trials has gone up, a new study shows. Analyzing the ClinicalTrials.gov database, researchers found that after trial registration became a requirement for publication in major scientific…
Combo Drug for Arthritis & Hypertension Meets Goal in Phase 3 Study
(Reuters)—Kitov Pharmaceuticals Holdings Ltd. said on Tuesday its lead drug, KIT-302, met the main goal of a late-stage study, reducing pain without increasing the risk of heart diseases in patients with osteoarthritis. Israel-based Kitov says its drug does not need to be labeled with health warnings, but will instead say it reduces the risk of…
Drug Approvals Top 2014 High, but R&D Returns Still Struggle
LONDON (Reuters)—The number of new drugs approved in the U.S. this year has already topped last year’s 18-year high, yet large pharmaceutical companies are still struggling to get a decent return on their research dollars. In fact, returns on research and development (R&D) spending by the world’s top drug makers have fallen to just 4.2%,…
Hospital Safety Culture Key to Improving Surgical Results
NEW YORK (Reuters Health)—The “safety culture” of a hospital may be just as important in delivering high-quality surgical patient care as more technical issues like surgeon skill and operating room equipment, according to a new study. “The study supports what many surgeons have known for a long time, and that is that the organizational culture…
Valeant Hires Attorney, Crisis Management Firm as U.S. Scrutiny Mounts
WASHINGTON/NEW YORK (Reuters)—Pharmaceuticals firm Valeant, under mounting pressure from Congress and prosecutors over its drug pricing, has hired an attorney in Washington, D.C., and crisis public relations experts with political connections, according to sources familiar with the matter. The move, confirmed by sources and through documents viewed by Reuters, signals a shift for Valeant Pharmaceuticals,…
Careful Management Improves Safety of Stem Cell Transplantation in Crohn’s
NEW YORK (Reuters Health)—Careful use of antibiotics and corticosteroids can substantially improve the safety of autologous hematopoietic stem transplantation (HSCT) in patients with refractory Crohn’s disease (CD), researchers from Spain report. “Autologous HSCT is feasible but it is associated with severe adverse events and even mortality,” Dr. Elena Ricart from Hospital Clinic de Barcelona tells…
- « Previous Page
- 1
- …
- 75
- 76
- 77
- 78
- 79
- …
- 98
- Next Page »